Medical Countermeasures Initiative Regulatory Science Symposium, 21785 [2012-8695]
Download as PDF
<![CDATA[
Federal Register / Vol. 77, No. 70 / Wednesday, April 11, 2012 / Notices
wreier-aviles on DSK5TPTVN1PROD with NOTICES
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before April 25, 2012. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before April 17,
2012. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by April 18, 2012.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Martha
Monser at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: April 5, 2012.
David Dorsey,
Acting Associate Commissioner for Policy and
Planning.
[FR Doc. 2012–8701 Filed 4–10–12; 8:45 am]
BILLING CODE 4160–01–P
VerDate Mar<15>2010
15:14 Apr 10, 2012
Jkt 226001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21785
Dated: April 6, 2012.
David Dorsey,
Acting Associate Commissioner for Policy and
Planning.
[FR Doc. 2012–8695 Filed 4–10–12; 8:45 am]
[Docket No. FDA–2012–N–0001]
BILLING CODE 4160–01–P
Medical Countermeasures Initiative
Regulatory Science Symposium
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
National Institutes of Health
Notice of meeting.
The Food and Drug Administration
(FDA) is announcing the following
meeting: Medical Countermeasures
Initiative Regulatory Science
Symposium. The symposium is
intended to provide a forum for the
exchange of ideas for medical
countermeasure development, highlight
work on regulatory science as it applies
to the development and advancement of
medical countermeasures, facilitate
innovative directions, and inform
stakeholders on medical
countermeasure-related scientific
progress and accomplishments.
Date and Time: This symposium will
be held on Tuesday, June 5 and
Wednesday, June 6, 2012, from 8 a.m. to
5:30 p.m. Persons interested in
attending the symposium in person or
viewing via Web cast must register by
Tuesday, May 29, 2012, at 5 p.m. EST.
Location: The symposium will be
held at the FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31,
rm. 1503, Silver Spring, MD 20993–
0002.
Contact: Rakesh Raghuwanshi, Office
of Counterterrorism and Emerging
Threats, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 32,
rm. 4283, 301–796–4769, FAX: 301–
847–8615, email: Rakesh.Raghuwanshi
@fda.hhs.gov.
Registration: If you wish to attend the
symposium or view via Web cast, you
must register at https://www.fda.gov/
medicalcountermeasures by Tuesday,
May 29, 2012, at 5 p.m. EST. When
registering, you must provide the
following information: (1) Your name,
(2) title, (3) company or organization (if
applicable), (4) mailing address, (5)
phone number, and (6) email address.
There is no fee to register for the
symposium and registration will be on
a first-come, first-served basis. Early
registration is recommended because
seating is limited. If you need special
accommodations due to a disability,
please enter pertinent information in the
‘‘Notes’’ section of the electronic
registration form when you register.
PO 00000
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Frm 00065
Fmt 4703
Sfmt 4703
Submission for OMB Review;
Comment Request: Prevalence,
Incidence, Epidemiology and
Molecular Variants of HIV in Blood
Donors in Brazil
Summary: Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Heart, Lung, and Blood Institute
(NHLBI), the National Institutes of
Health (NIH) has submitted to the Office
of Management and Budget (OMB) a
request for review and approval of the
information collection listed below.
This proposed information collection
was previously published in the Federal
Register on January 13, 2012, page 2072,
and allowed 60 days for public
comment. No public comments were
received. The purpose of this notice is
to allow an additional 30 days for public
comment. The National Institutes of
Health may not conduct or sponsor, and
the respondent is not required to
respond to, an information collection
that has been extended, revised, or
implemented on or after October 1,
1995, unless it displays a currently valid
OMB control number.
Proposed Collection: Title:
Prevalence, Incidence, Epidemiology
and Molecular Variants of HIV in Blood
Donors in Brazil. Type of Information
Collection Request: Reinstatement
(OMB No. 0925–0597). Need and Use of
Information Collection: Establishing and
monitoring viral prevalence and
incidence rates, and identifying
behavioral risk behaviors for HIV
infection among donors are critical steps
to assessing and reducing risk of HIV
transmission through blood transfusion.
Detecting donors with recently acquired
HIV infection is particularly critical as
it enables characterization of the viral
subtypes currently transmitted within
the screened population. In addition to
characterizing genotypes of recently
infected donors for purposes of blood
safety, molecular surveillance of
incident HIV infections in blood donors
serves important public health roles by
identifying new HIV infections for antiretroviral treatment, and enabling
documentation of the rates of primary
E:\FR\FM\11APN1.SGM
11APN1
]]>Agencies
[Federal Register Volume 77, Number 70 (Wednesday, April 11, 2012)]
[Notices]
[Page 21785]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-8695]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0001]
Medical Countermeasures Initiative Regulatory Science Symposium
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is announcing the following
meeting: Medical Countermeasures Initiative Regulatory Science
Symposium. The symposium is intended to provide a forum for the
exchange of ideas for medical countermeasure development, highlight
work on regulatory science as it applies to the development and
advancement of medical countermeasures, facilitate innovative
directions, and inform stakeholders on medical countermeasure-related
scientific progress and accomplishments.
Date and Time: This symposium will be held on Tuesday, June 5 and
Wednesday, June 6, 2012, from 8 a.m. to 5:30 p.m. Persons interested in
attending the symposium in person or viewing via Web cast must register
by Tuesday, May 29, 2012, at 5 p.m. EST.
Location: The symposium will be held at the FDA White Oak Campus,
10903 New Hampshire Ave., Bldg. 31, rm. 1503, Silver Spring, MD 20993-
0002.
Contact: Rakesh Raghuwanshi, Office of Counterterrorism and
Emerging Threats, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 32, rm. 4283, 301-796-4769, FAX: 301-847-8615, email:
Rakesh.Raghuwanshi @fda.hhs.gov.
Registration: If you wish to attend the symposium or view via Web
cast, you must register at https://www.fda.gov/medicalcountermeasures by
Tuesday, May 29, 2012, at 5 p.m. EST. When registering, you must
provide the following information: (1) Your name, (2) title, (3)
company or organization (if applicable), (4) mailing address, (5) phone
number, and (6) email address.
There is no fee to register for the symposium and registration will
be on a first-come, first-served basis. Early registration is
recommended because seating is limited. If you need special
accommodations due to a disability, please enter pertinent information
in the ``Notes'' section of the electronic registration form when you
register.
Dated: April 6, 2012.
David Dorsey,
Acting Associate Commissioner for Policy and Planning.
[FR Doc. 2012-8695 Filed 4-10-12; 8:45 am]
BILLING CODE 4160-01-P
